RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
IPO Year: 2021
Exchange: NASDAQ
Website: rxsight.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $72.00 | Buy | Jefferies |
| 8/20/2024 | $54.00 → $66.00 | Buy | Needham |
| 8/6/2024 | $75.00 → $54.00 | Buy | Needham |
| 5/7/2024 | $61.00 → $72.00 | Buy | BTIG Research |
| 12/13/2023 | $31.00 → $42.00 | Equal Weight → Overweight | Wells Fargo |
| 12/12/2023 | $40.00 | Buy | Stifel |
| 12/4/2023 | $36.00 | Overweight | Morgan Stanley |
| 4/13/2023 | $23.00 | Outperform | Oppenheimer |
| 12/12/2022 | $20.00 → $14.00 | Overweight → Equal Weight | Wells Fargo |
| 4/8/2022 | $18.00 | Buy | Needham |
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
Jefferies initiated coverage of RxSight with a rating of Buy and set a new price target of $72.00
Needham reiterated coverage of RxSight with a rating of Buy and set a new price target of $66.00 from $54.00 previously
Needham reiterated coverage of RxSight with a rating of Buy and set a new price target of $54.00 from $75.00 previously
BTIG Research reiterated coverage of RxSight with a rating of Buy and set a new price target of $72.00 from $61.00 previously
Wells Fargo upgraded RxSight from Equal Weight to Overweight and set a new price target of $42.00 from $31.00 previously
Stifel initiated coverage of RxSight with a rating of Buy and set a new price target of $40.00
Morgan Stanley initiated coverage of RxSight with a rating of Overweight and set a new price target of $36.00
Oppenheimer initiated coverage of RxSight with a rating of Outperform and set a new price target of $23.00
Wells Fargo downgraded RxSight from Overweight to Equal Weight and set a new price target of $14.00 from $20.00 previously
Needham initiated coverage of RxSight with a rating of Buy and set a new price target of $18.00
Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17. Earnings Estimates: Analysts expect Johnson & Johnson to report second-quarter revenue of $22.31 billion, according to data from Benzinga Pro. The company reported revenue of $25.53 billion in last year's second quarter, meaning analysts see a revenue decline on a year-over-year basis. Johnson & Johnson has beaten revenue estimates in six of the past 10 quarters and four of the last five quarters.
7 analysts have shared their evaluations of RxSight (NASDAQ:RXST) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 2 0 0 0 Analysts have recently evaluated RxSight and provided 12-month price targets. The average target is $71.14, accompanied by a high estimate of $75.00 and a low estimate of $68.00. Marking an increase
BTIG analyst Ryan Zimmerman maintains RxSight (NASDAQ:RXST) with a Buy and raises the price target from $72 to $73.
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55 per share. SeaStar Medical shares dipped 34% to $8.55 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares jumped 139% to $2.78 after the company announced results for a Swine Model pilot study for Probudur. Kazia Therapeutics Limited (NASDAQ:KZIA) gained 129% to $0.4325 after the company announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of
Stifel analyst Thomas Stephan maintains RxSight (NASDAQ:RXST) with a Buy and lowers the price target from $75 to $70.
RxSight Inc (NASDAQ:RXST) shares are roughly flat following earlier weakness during Thursday's session after the company announced pricing of its $100 million proposed public offering of common stock. The company plans to sell 1,785,714 shares of common stock at $56.00 per share, with an option for underwriters to purchase an additional 267,857 shares. Gross proceeds are estimated at around $100 million. The offering is expected to close on May 13. BofA Securities is the lead bookrunning manager, with J.P. Morgan as a bookrunning manager and BTIG as co-manager. RxSight intends to use the proceeds for commercial expansion, international growth, product development, research and general
RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight.
RxSight, Inc., (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering on the same terms and conditions. RxSight intends to use the net proceeds from the offering for continued commercial and marketing expansion, including international expansion, funding of product development,
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
4 - RxSight, Inc. (0001111485) (Issuer)
ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights Reported third quarter 2024 revenue of $35.3 million, an increase of 59% compared to the third quarter of 2023, reflecting: The sale of 24,554 Light Adjustable Lenses (LAL™/LAL+™), representing an 80% increase in procedure volume compared to the third quarter of 2023; andThe sale of 78 Light Delivery Devices (LDD™s), representing a 18% increase in unit sales compared to
ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (888) 596-4144 or (646) 968-2525, and enter the conference code: 7406253. The call will also be broadcast live in listen-only mode via a link on the company's investor re
ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced its plans to participate in two upcoming healthcare conferences in September. Morgan Stanley 22nd Annual Global Healthcare Conference- Fireside Chat: Wednesday, September 4, 2024, at 9:15 a.m. ET in New York City, NY Wells Fargo 2024 Healthcare Conference- Fireside Chat: Thursday, September 5, 2024, at 3:45 p.m. ET in Boston, MA Interested parties may access live and archived webcasts of these events at https://investors.rxsight.com/. About RxSight, Inc. R
ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024. Key Quarterly Highlights Reported second quarter 2024 revenue of $34.9 million, an increase of 68% compared to the second quarter of 2023, reflecting: The sale of 24,214 Light Adjustable Lenses (LAL™/LAL+™), representing a 92% increase in procedure volume compared to the second quarter of 2023;The sale of 78 Light Delivery Devices (LDD™s), representing a 16% increase in unit sales compared to the sec
ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call please register here. While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applicati
ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference. RxSight's management is scheduled to participate in a fireside chat on Tuesday, June 18, 2024, at 12:05 p.m. Pacific Time / 3:05 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients f
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase up to 267,857 additional shares. RxSight's gross proceeds from the offering were $115.0 million, before deducting underwriting discounts and commissions and other offering expenses. BofA Securities acted as lead bookrunning manager of the offering
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are to be sold by RxSight. Before deducting the underwriting discount and estimated offerin
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering on the same terms and conditions. RxSight intends to use the net proceeds from the offering for continued commercial and marketing expansion, including
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
SC 13G - RxSight, Inc. (0001111485) (Subject)
SC 13G - RxSight, Inc. (0001111485) (Subject)
SC 13D/A - RxSight, Inc. (0001111485) (Subject)
SC 13D/A - RxSight, Inc. (0001111485) (Subject)
SC 13G/A - RxSight, Inc. (0001111485) (Subject)
10-Q - RxSight, Inc. (0001111485) (Filer)
8-K - RxSight, Inc. (0001111485) (Filer)
10-Q - RxSight, Inc. (0001111485) (Filer)
8-K - RxSight, Inc. (0001111485) (Filer)
144 - RxSight, Inc. (0001111485) (Subject)
8-K - RxSight, Inc. (0001111485) (Filer)
SD - RxSight, Inc. (0001111485) (Filer)
424B5 - RxSight, Inc. (0001111485) (Filer)
8-K - RxSight, Inc. (0001111485) (Filer)
424B5 - RxSight, Inc. (0001111485) (Filer)
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig
ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended September 30, 2024. Key Quarterly Highlights Reported third quarter 2024 revenue of $35.3 million, an increase of 59% compared to the third quarter of 2023, reflecting: The sale of 24,554 Light Adjustable Lenses (LAL™/LAL+™), representing an 80% increase in procedure volume compared to the third quarter of 2023; andThe sale of 78 Light Delivery Devices (LDD™s), representing a 18% increase in unit sales compared to
ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (888) 596-4144 or (646) 968-2525, and enter the conference code: 7406253. The call will also be broadcast live in listen-only mode via a link on the company's investor re
ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the second quarter of 2024 after the market close on Monday, August 5, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call please register here. While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applicati
ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+™), representing a 92% increase in procedure volume compared to the first quarter of 2023;The sale of 66 Light Delivery Devices (LDD™s), representing an 18% increase in unit sales compar
ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the first quarter of 2024 after the market close on Monday, May 6, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call please register here. While not required, it is recommended that participants join ten minutes prior to the event start time to ensure the necessary audio applications are
ALISO VIEJO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months and full year ended December 31, 2023. Key Quarterly and Full Year Highlights Recognized fourth quarter 2023 revenue of $28.6 million, an increase of 78% compared to the fourth quarter of 2022, reflecting: The sale of 77 Light Delivery Devices (LDD™s), representing a 35% unit increase from the fourth quarter of 2022, expanding the installed base to 666 LDDs at the end of the quarter, a 67% increase compared to the 400-uni
ALISO VIEJO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter and full year 2023 after the market close on Wednesday, February 28, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is r
ALISO VIEJO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and nine months ended September 30, 2023. Key Quarterly Highlights Reported third quarter 2023 revenue of $22.2 million, an increase of 76% compared to the third quarter of 2022, reflecting: The sale of 66 Light Delivery Devices (LDD™s), representing a 35% increase in unit sales compared to the third quarter of 2022 and expanding the installed base to 589 LDDs at the end of the quarter, representing a 72% i
ALISO VIEJO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the third quarter 2023 after the market close on Thursday, November 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/. While not required, it is recommended that par
ALISO VIEJO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three and six months ended June 30, 2023. Key Quarterly Highlights Reported second quarter 2023 revenue of $20.8 million, an increase of 83% compared to the second quarter of 2022, reflecting: The sale of 67 Light Delivery Devices (LDD™s), representing a 37% increase in unit sales compared to the second quarter of 2022 and expanding the installed base to 523 LDDs at the end of the quarter, representing a 78% increase compared to end of the second qu